Published in

Springer (part of Springer Nature), Cancer Chemotherapy and Pharmacology, 1(64), p. 199-200

DOI: 10.1007/s00280-009-0971-3

Links

Tools

Export citation

Search in Google Scholar

Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

5-Fluoro-uracil (5FU), an antimetabolite drug, stimulates expression of topoisomerase I (tpI) in adenocarcinoma cancer cells. When 5FU is given in combination with Irinotecan (IR), a tpI poison, the most effective regimen is represented by IR given before low doses of 5FU. Hence, despite their distinct mechanisms of action, the molecular basis for successful combination and schedule of 5FU and IR in the treatment of colorectal cancer rests on the opposing drug effects on the expression and poisoning of the tpI enzyme.